CA3207919A1 - Procedes et compositions pour moduler l'activite fgf - Google Patents

Procedes et compositions pour moduler l'activite fgf Download PDF

Info

Publication number
CA3207919A1
CA3207919A1 CA3207919A CA3207919A CA3207919A1 CA 3207919 A1 CA3207919 A1 CA 3207919A1 CA 3207919 A CA3207919 A CA 3207919A CA 3207919 A CA3207919 A CA 3207919A CA 3207919 A1 CA3207919 A1 CA 3207919A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
pharmaceutical composition
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3207919A
Other languages
English (en)
Inventor
Seth P. Finklestein
Gregory D. Cuny
Renato Skerlj
Soumya Ray
Stephen Douglas Barrett
Kirk Lang Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recovery Therapeutics Inc
Original Assignee
Recovery Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recovery Therapeutics Inc filed Critical Recovery Therapeutics Inc
Publication of CA3207919A1 publication Critical patent/CA3207919A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des composés et un procédé de traitement d'une lésion ou d'une maladie, par exemple, un accident vasculaire cérébral, un hypogonadisme hypogonadotrope congénitale et une infection virale, à l'aide des composés. L'invention concerne également une composition pharmaceutique contenant un ou plusieurs des composés, et un procédé d'augmentation de la spermatogenèse à l'aide des composés.
CA3207919A 2021-02-12 2022-02-11 Procedes et compositions pour moduler l'activite fgf Pending CA3207919A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148900P 2021-02-12 2021-02-12
US63/148,900 2021-02-12
PCT/US2022/016159 WO2022174062A1 (fr) 2021-02-12 2022-02-11 Procédés et compositions pour moduler l'activité fgf

Publications (1)

Publication Number Publication Date
CA3207919A1 true CA3207919A1 (fr) 2022-08-18

Family

ID=82837938

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3207919A Pending CA3207919A1 (fr) 2021-02-12 2022-02-11 Procedes et compositions pour moduler l'activite fgf

Country Status (8)

Country Link
US (1) US20240173311A1 (fr)
EP (1) EP4291221A1 (fr)
JP (1) JP2024506398A (fr)
CN (1) CN117202923A (fr)
AU (1) AU2022218797A1 (fr)
CA (1) CA3207919A1 (fr)
IL (1) IL305073A (fr)
WO (1) WO2022174062A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992469B2 (en) * 2020-09-22 2024-05-28 City University Of Hong Kong Targeting mitochondrial dynamics by mitochondrial fusion promoter M1 as a treatment strategy for nervous system injury

Also Published As

Publication number Publication date
US20240173311A1 (en) 2024-05-30
CN117202923A (zh) 2023-12-08
JP2024506398A (ja) 2024-02-13
IL305073A (en) 2023-10-01
WO2022174062A1 (fr) 2022-08-18
EP4291221A1 (fr) 2023-12-20
AU2022218797A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
US20030186961A1 (en) Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
EP3444249B1 (fr) Bloqueurs de canal sodique, leur procédé de préparation et leur utilisation
CN111116492B (zh) 氘代苯甲氨嘧啶二酮衍生物及其用途
CN102264743A (zh) Mlk抑制剂及其使用方法
JP6302480B2 (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
BR112020018933A2 (pt) Composto, composição farmacêutica, método de tratamento de um transtorno associado a kv7 e método de tratamento de um transtorno associado a uma mutação kcnq2
CA3207919A1 (fr) Procedes et compositions pour moduler l&#39;activite fgf
WO2001008705A1 (fr) Remedes contre les douleurs neurogenes
DE10252102A1 (de) Indolderivate
US20240174631A1 (en) Compounds, compositions, and methods for modulating fgf activity
CA3098988A1 (fr) Derive heterocyclique
US7253169B2 (en) Aza compounds, pharmaceutical compositions and methods of use
WO2020013108A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies mitochondriales
EP2514753B1 (fr) Dérivés de la 6,7-dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepine et compositions pharmaceutiques contenant ceux-ci en tant qu&#39;agent hypnotique ou anesthésique et procédé pour leur préparation
EP3423444B1 (fr) Nouveaux types de dérivés d&#39;acide kynurénique substitués en c-3 ayant une activité neuroprotectrice améliorée
JP2003514799A (ja) ニューロン活性を有するアザ化合物
NL8401890A (nl) Carbonzuuramideverbindingen en derivaten daarvan.
US20050130978A1 (en) Novel crystal of quinoxalinedione derivative anhydride
JP2003514799A5 (fr)
EP4074707A1 (fr) Composé à effet neuroprotecteur, son procédé de préparation et son utilisation
CN118063445A (zh) 吡咯烷酰胺衍生物及其用途
WO2020114465A1 (fr) Préparation et utilisation d&#39;un composé d&#39;iminazole hétéroaromatique
MC MK et al. compositions containing the same as hypnotic or anesthetic agent and method for their preparation
WO2001079177A1 (fr) Composes diaza cycliques pour le traitement de troubles neurodegeneratifs
IL143392A (en) Carboxylic acid isosteres of n- heterocyclic compounds and pharmaceutical compositions for treating neurological disorders comprising them